3 Power and Distribution Transformers Maker, Electrical Cables Maker and Pharmaceutical Company Stocks With a Strong Future Roadmap: Atlanta Electricals, Finolex Cables and Mankind Pharma

Transformer, cable and pharma stocks let investors follow companies that serve a growing part of the Indian economy. Atlanta Electricals, Finolex Cables and Mankind Pharma cover a transformers maker, an electrical cables maker and a pharmaceutical company.

This list covers three transformer, cable and pharma stocks with complete current figures: Atlanta Electricals, Finolex Cables and Mankind Pharma. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Transformer, Cable and Pharma Stocks?

Transformer, cable and pharma stocks are listed companies that make power and distribution transformers, produce electrical and communication cables, and sell branded medicines and consumer health products across India. Their earnings depend on grid investment, building activity and prescription demand.

Transformer, Cable and Pharma Stocks at a Glance

On valuation, Finolex Cables trades at a P/E below the industry P/E, while Atlanta Electricals and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing transformer, cable and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in transformer, cable and pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Transformer, Cable and Pharma Stocks Have a Strong Roadmap in India?

Transformer, cable and pharma stocks have a strong roadmap in India because heavy investment in power transmission, rising construction and wiring needs and growing demand for chronic and acute care medicines keep widening the market for these companies.

• Transformers. Grids need new capacity.
• Cables. New buildings and networks need wiring.
• Pharma. Doctors prescribe branded medicines widely.

Why Atlanta Electricals Features Among These Transformer, Cable and Pharma Stocks

Among the transformer, cable and pharma stocks on this list, Atlanta Electricals, based in Gujarat, manufactures power and distribution transformers and related electrical equipment for utilities and industrial customers.

The company has a return on equity of 21.7%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 12,995 crore. The stock trades at a P/E of 59.8, above the industry P/E of 43.9.

Revenue rose from Rs 597 crore in FY22 to Rs 1,867 crore in FY26, a compound annual growth rate of 33.0%. Net profit grew from Rs 87.5 crore in FY23 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 32.1%. In the June 2026 quarter, revenue grew 47.6% year on year to Rs 469 crore, while net profit rose 50.4% to Rs 46.8 crore.

Roadmap: Transmission and distribution spending, rising electricity demand and renewable power connections keep the transformer order book active. The company is adding capacity to meet this demand and to serve larger customers.

What to watch: Monitor order backlog conversion and the pace of capacity additions.

Why Finolex Cables Features Among These Transformer, Cable and Pharma Stocks

Among the grid equipment, wire and medicine shares on this list, Finolex Cables is a Pune-based maker of electrical cables and wires, communication cables, copper products and consumer electricals such as fans, lighting and switchgear, sold under the Finolex brand.

Revenue rose from Rs 3,840 crore in FY22 to Rs 6,487 crore in FY26, a compound annual growth rate of 14.0%. Net profit grew from Rs 504 crore in FY23 to Rs 714 crore in FY26, which works out to a compound annual growth rate of 12.3%.

In the June 2026 quarter, revenue grew 42.4% year on year to Rs 2,065 crore, while net profit rose 53.1% to Rs 249 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 19,615 crore. The stock trades at a P/E of 24.5, below the industry P/E of 45.1.

Roadmap: Strong brand recall among electricians and a wide distribution network support its position in housing wires. Infrastructure, housing and telecom projects add to demand for its cables and related electricals.

What to watch: Track growth in the electrical consumer products business and copper price trends.

Why Mankind Pharma Features Among These Transformer, Cable and Pharma Stocks

Among the three companies on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%.

Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Atlanta Electricals vs Finolex Cables vs Mankind Pharma on Key Financials

The table below sets the three transformer, cable and pharma stocks side by side on revenue, profit and margin, using reported figures.

Atlanta Electricals posts the highest return on equity in this group at 21.7%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Atlanta Electricals shows the fastest revenue growth with a 33.0% compound annual rate. A useful habit with transformer, cable and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Transformer, Cable and Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these transformer, cable and pharma stocks, the main points are: Long-term grid equipment, wire and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Component costs. Copper, chips and other inputs can move margins.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter transformer, cable and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Transformer, Cable and Pharma Stocks

Transformer, cable and pharma stocks reward investors who follow demand trends, order books and margins together. Atlanta Electricals, Finolex Cables and Mankind Pharma each have a clear plan to grow. Based on the 5 November 2026 close, Atlanta Electricals trades at Rs 1,473.7, Finolex Cables at Rs 1,174.3 and Mankind Pharma at Rs 2,518. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these transformer, cable and pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track transformer, cable and pharma stocks, set price alerts and get research-backed stock ideas.

What are transformer, cable and pharma stocks?

Ans. Transformer, cable and pharma stocks are listed companies that make power and distribution transformers, produce electrical and communication cables, and sell branded medicines and consumer health products across India. Their earnings depend on grid investment, building activity and prescription demand. This list looks at three of them, Atlanta Electricals, Finolex Cables and Mankind Pharma, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.

Which transformer, cable and pharma stocks are covered in this list?

Ans. This list covers Atlanta Electricals, Finolex Cables and Mankind Pharma. Based on the 5 November 2026 close, Atlanta Electricals traded at Rs 1,473.7, Finolex Cables at Rs 1,174.3 and Mankind Pharma at Rs 2,518. Their return on equity ranges from 11.7% to 21.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.0% to 33.0%.

Why do transformer, cable and pharma stocks have a strong future roadmap in India?

Ans. Transformer, cable and pharma stocks have a strong roadmap in India because heavy investment in power transmission, rising construction and wiring needs and growing demand for chronic and acute care medicines keep widening the market for these companies. The main drivers are as follows. Transformers. Grids need new capacity. Cables. New buildings and networks need wiring. Pharma. Doctors prescribe branded medicines widely. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Atlanta Electricals performed financially?

Ans. Revenue rose from Rs 597 crore in FY22 to Rs 1,867 crore in FY26, a compound annual growth rate of 33.0%. Net profit grew from Rs 87.5 crore in FY23 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 32.1%. In the June 2026 quarter, revenue grew 47.6% year on year to Rs 469 crore, while net profit rose 50.4% to Rs 46.8 crore. The company has a return on equity of 21.7%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 12,995 crore. The stock trades at a P/E of 59.8, above the industry P/E of 43.9. Looking ahead, transmission and distribution spending, rising electricity demand and renewable power connections keep the transformer order book active. The company is adding capacity to meet this demand and to serve larger customers.

How has Finolex Cables performed financially?

Ans. Revenue rose from Rs 3,840 crore in FY22 to Rs 6,487 crore in FY26, a compound annual growth rate of 14.0%. Net profit grew from Rs 504 crore in FY23 to Rs 714 crore in FY26, which works out to a compound annual growth rate of 12.3%. In the June 2026 quarter, revenue grew 42.4% year on year to Rs 2,065 crore, while net profit rose 53.1% to Rs 249 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 19,615 crore. The stock trades at a P/E of 24.5, below the industry P/E of 45.1. Looking ahead, strong brand recall among electricians and a wide distribution network support its position in housing wires. Infrastructure, housing and telecom projects add to demand for its cables and related electricals.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What risks should investors check before buying transformer, cable and pharma stocks?

Ans. Investors should check a few risks before buying transformer, cable and pharma stocks. Component costs. Copper, chips and other inputs can move margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of transformer, cable and pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.